KIF21A Protein
Overview
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">KIF21A Protein</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Position</td>
</tr>
<tr>
<td class="label">Motor Domain</td>
<td>N-terminus (1-380 aa)</td>
</tr>
<tr>
<td class="label">Coiled-coil Region 1</td>
<td>400-600 aa</td>
</tr>
<tr>
<td class="label">Coiled-coil Region 2</td>
<td>700-900 aa</td>
</tr>
<tr>
<td class="label">WD40 Repeat Domain</td>
<td>900-1200 aa</td>
</tr>
<tr>
<td class="label">Tail Domain</td>
<td>C-terminus (1200-1640 aa)</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>KIF21A</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>12q12</td>
</tr>
<tr>
<td class="label">Inheritance</td>
<td>Autosomal Dominant</td>
</tr>
<tr>
<td class="label">Pathogenic Variants</td>
<td>Missense, nonsense</td>
</tr>
<tr>
<td class="label">Phenotypic Spectrum</td>
<td>CFEOM3, HSP, peripheral neuropathy</td>
</tr>
<tr>
<td class="label">Population Frequency</td>
<td>Rare (<1/100,000)</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
KIF21A (Kinesin Family Member 21A) is a neuronal-specific kinesin motor protein belonging to the kinesin-4 family. It plays critical roles in microtubule-based intracellular transport, neuronal development, axonal growth, and synaptic function[@kano2006]. KIF21A is primarily expressed in [neurons](/entities/neurons) of the central and peripheral nervous systems, where it facilitates the long-range transport of various cargoes along axonal and dendritic microtubule tracks.
Mutations in KIF21A are classically associated with congenital fibrosis of the extraocular muscles (CFEOM), but emerging research reveals broader implications for neurodegenerative diseases including Alzheimer's Disease (AD), Parkinson's Disease (PD), and hereditary spastic paraplegia (HSP)[@tiab2004].
Structure
KIF21A is a ~1640 amino acid motor protein with a distinctive domain architecture:
The N-terminal motor domain hydrolyzes ATP to generate force for plus-end-directed movement along microtubules, characteristic of kinesin-4 family members[@hirose2014]. The C-terminal regulatory domain contains WD40 repeats that mediate cargo specificity and may interact with adaptor proteins.
Normal Physiological Function
Neuronal Transport
KIF21A functions as a critical molecular motor in neurons:
- Axonal Transport: Facilitates anterograde transport of vesicles, protein complexes, and organelles from the cell body to synaptic terminals
- Dendritic Transport: Regulates cargo delivery within dendritic arbors
- Synaptic Vesicle Precursors: Transports synaptic vesicle precursors to presynaptic terminals
- Mitochondrial Distribution: Contributes to mitochondrial trafficking and distribution in neurons
- Neurotrophin Signaling: Facilitates transport of neurotrophin receptors and signaling complexes
Neuronal Development
During development, KIF21A regulates:
- Axon Guidance: Modulates growth cone dynamics and steering
- Dendrite Morphogenesis: Controls dendritic branching and elaboration
- Synapse Formation: Facilitates presynaptic assembly
- Axon Initial Segment Targeting: Participates in protein localization at the axon initial segment
Microtubule Interactions
KIF21A exhibits unique microtubule interactions:
- Prefers acetylated microtubules commonly found in axons
- Can track microtubule plus-ends during processive movement
- May regulate microtubule stability in growth cones
- Interacts with microtubule-associated proteins (MAPs) including [tau](/proteins/tau)[@brunden2009]
Role in Neurodegenerative Diseases
Alzheimer's Disease
Axonal transport deficits are recognized as early hallmarks of AD pathogenesis. KIF21A dysfunction may contribute to:
- Amyloid-β Transport Dysregulation: Impaired clearance of amyloid-β from axons
- [Tau](/proteins/tau)-Mediated Inhibition: Hyperphosphorylated [tau](/proteins/tau) disrupts microtubule integrity and kinesin-based transport
- Synaptic Vesicle Depletion: Reduced delivery of synaptic components to nerve terminals
- Axonal Swelling: Accumulation of stalled cargoes leads to characteristic axonal spheroids
- Neuronal Hypometabolism: Transport deficits contribute to reduced synaptic activity
The [amyloid precursor protein (APP)](/proteins/app) and its cleavage products interact with kinesin motors, and alterations in this relationship contribute to AD pathology[@cai2005].
Parkinson's Disease
KIF21A involvement in PD relates to:
- Dopaminergic Neuron Vulnerability: Selective degeneration of [SNCA](/proteins/alpha-synuclein)-expressing neurons
- Synaptic α-Synuclein Pathology: Impaired transport may exacerbate α-synuclein aggregation
- Mitochondrial Dysfunction: Reduced mitochondrial delivery to energy-demanding synapses
- Axonal Degeneration: Transport deficits precede cell body loss
- Lysosomal Traffic: Altered delivery of lysosomal enzymes
The [LRRK2](/proteins/lrrk2-protein) kinase, a major PD genetic risk factor, can phosphorylate kinesin light chains, affecting transport function[@godena2014].
Hereditary Spastic Paraplegia (HSP)
KIF21A mutations cause autosomal dominant congenital fibrosis of extraocular muscles type 3A (CFEOM3A), which shares features with HSP:
- Axonal Transport Impairment: Dominant-negative effects on transport
- Microtubule Dysregulation: Altered microtubule stability
- Progressive Neuropathy: Age-dependent axonal degeneration
- Upper Motor Neuron Involvement: Spasticity resulting from corticospinal tract dysfunction
Amyotrophic Lateral Sclerosis (ALS)
KIF21A transport deficits may contribute to motor neuron vulnerability:
- RNA Granule Transport: Disrupted transport of mRNA and translation machinery
- Synaptic Dysfunction: Impaired neuromuscular junction maintenance
- Axonal Energy Deficit: Reduced mitochondrial delivery
- Protein Aggregate Clearance: Defective transport of ubiquitinated proteins
Pathway Interactions
KIF21A participates in several key cellular pathways:
Mermaid diagram (expand to render)
Key pathway interactions include:
- MAPK/Tau Pathway: [Tau](/proteins/tau) phosphorylation state affects KIF21A function
- SNARE Complex Assembly: Synaptic vesicle precursors require KIF21A transport
- Mitochondrial Dynamics: Miro1/Trak proteins coordinate mitochondrial-kinesin interactions
- Neurotrophin Signaling: [BDNF](/proteins/bdnf-protein) and TrkB transport
Clinical Genetics
Therapeutic Implications
Drug Development Strategies
- Microtubule-Stabilizing Agents: Taxanes and epothilones enhance transport efficiency
- Kinesin Motor Modulators: Small molecules targeting motor domain function
- ATPase Inhibitors: Modulate KIF21A activity pharmacologically
- Phosphorylation Modulators: Target kinases (GSK3β, CDK5) that regulate kinesin function
Gene Therapy Approaches
- Wild-type KIF21A Delivery: AAV-mediated gene replacement
- Allele-Specific Silencing: For dominant-negative mutations
- CRISPR-Cas9 Editing: Precise correction of pathogenic variants
- mRNA Therapeutics: Transient expression of functional proteins
Biomarker Development
- Transport Kinetics: Live-cell imaging of fluorescent cargo movement
- KIF21A Expression: CSF and blood biomarkers
- Phosphorylation Status: p-KIF21A as disease progression marker
Research Outlook
Key research questions remain:
KIF21A-Specific Cargo: What are the exact cargoes transported by KIF21A?
Regulation Mechanisms: How is KIF21A activity regulated by neuronal signaling?
Disease Modifiers: What genetic factors modify KIF21A-related neurodegeneration?
Therapeutic Targeting: Can KIF21A function be selectively enhanced?See Also
- [KIF21A Gene](/genes/kif21a)
- [Synaptic Transmission](/mechanisms/synaptic-transmission)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [GeneCards: KIF21A](https://www.genecards.org/cgi-bin/carddisp.pl?gene=KIF21A)
Related Pages
- [Tau Protein](/proteins/tau)
- [Alpha](/mechanisms/dopaminergic-neuron-vulnerability)
- [APP Protein](/proteins/app)
- [LRRK2 Protein](/genes/park2)
- [Kinesin](/proteins/kinesin-1a-protein)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
References
[Kano et al., KIF21A is a novel neuronal kinesin, J Cell Biol 2006 (2006)](https://pubmed.ncbi.nlm.nih.gov/16418556/)
[Tiab et al., KIF21A mutations causing CFEOM, Invest Ophthalmol Vis Sci 2004 (2004)](https://pubmed.ncbi.nlm.nih.gov/15523086/)
[Hirose et al., Crystal structure of KIF21A motor domain, Nat Struct Mol Biol 2014 (2014)](https://pubmed.ncbi.nlm.nih.gov/24703847/)
[Brunden et al., Axonal transport deficits in Alzheimer's disease, Nat Rev Neurosci 2009 (2009)](https://pubmed.ncbi.nlm.nih.gov/19559335/)
[Cai et al., APP and kinesin axonal transport, J Neurosci 2005 (2005)](https://pubmed.ncbi.nlm.nih.gov/15987845/)
[Godena et al., LRRK2 regulates mitochondrial transport, Curr Biol 2014 (2014)](https://pubmed.ncbi.nlm.nih.gov/25447999/)
[Baas et al., Microtubule-based transport therapy, Neurotherapeutics 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/30635842/)